BRPI0506839A - composições e métodos para induzir a cardiomiogênese - Google Patents

composições e métodos para induzir a cardiomiogênese

Info

Publication number
BRPI0506839A
BRPI0506839A BRPI0506839-8A BRPI0506839A BRPI0506839A BR PI0506839 A BRPI0506839 A BR PI0506839A BR PI0506839 A BRPI0506839 A BR PI0506839A BR PI0506839 A BRPI0506839 A BR PI0506839A
Authority
BR
Brazil
Prior art keywords
methods
compositions
inducing cardiomyogenesis
cardiomyogenesis
inducing
Prior art date
Application number
BRPI0506839-8A
Other languages
English (en)
Inventor
Xu Wu
Sheng Ding
Peter G Schultz
Original Assignee
Novartis Ag
Scripps Res Insittute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Scripps Res Insittute filed Critical Novartis Ag
Publication of BRPI0506839A publication Critical patent/BRPI0506839A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO E MéTODOS PARA INDUZIR A CARDIOMIOGêNESE. A presente invenção refere-se a composição e métodos para induzir cardiomiogênese em células mamíferas, particulamente células tronco embriónicas, in vitro e in vivo.
BRPI0506839-8A 2004-01-16 2005-01-14 composições e métodos para induzir a cardiomiogênese BRPI0506839A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53714404P 2004-01-16 2004-01-16
PCT/EP2005/000323 WO2005068437A1 (en) 2004-01-16 2005-01-14 2, 4 - diaminopyrimidines and their use for inducing cardiomyogenesis

Publications (1)

Publication Number Publication Date
BRPI0506839A true BRPI0506839A (pt) 2007-06-12

Family

ID=34794442

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506839-8A BRPI0506839A (pt) 2004-01-16 2005-01-14 composições e métodos para induzir a cardiomiogênese

Country Status (10)

Country Link
US (1) US20050209231A1 (pt)
EP (1) EP1727806A1 (pt)
JP (1) JP2007517831A (pt)
KR (1) KR20060133552A (pt)
CN (1) CN1910159A (pt)
AU (1) AU2005205167A1 (pt)
BR (1) BRPI0506839A (pt)
CA (1) CA2551770A1 (pt)
RU (1) RU2006129469A (pt)
WO (1) WO2005068437A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2626234T3 (es) 2004-07-30 2017-07-24 Mayo Foundation For Medical Education And Research Tratamiento de tejido cardiovascular
EP2054392A2 (en) * 2006-06-15 2009-05-06 Boehringer Ingelheim International GmbH 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
KR20090023698A (ko) * 2006-06-15 2009-03-05 베링거 인겔하임 인터내셔날 게엠베하 2-아닐리노-4-아미노알킬렌아미노피리미딘
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
KR100937457B1 (ko) * 2007-08-10 2010-01-19 한국생명공학연구원 인간배아줄기세포와 인간배아종양세포를 심근세포 직계열로분화시키는 방법
KR101738323B1 (ko) 2007-09-19 2017-05-19 플루리스템 리미티드 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
US9719146B2 (en) * 2009-09-09 2017-08-01 General Electric Company Composition and method for imaging stem cells
AT509266B1 (de) * 2009-12-28 2014-07-15 Univ Wien Tech Substituierte pyridine und pyrimidine
EA201290642A1 (ru) * 2010-01-13 2013-05-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Соединения и способы
WO2014152809A2 (en) * 2013-03-14 2014-09-25 The University Of Toledo Analogs of pparo and 20-oh-pge2, and methods of using the same
WO2018055235A1 (en) * 2016-09-21 2018-03-29 University Of Helsinki Isoxazole-amides for treating cardiac diseases
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
JP7668621B2 (ja) 2019-03-29 2025-04-25 健裕生技股▲分▼有限公司 心筋再生を促進させるための化合物、その調製方法、医薬組成物及びこれらの使用
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN115141150B (zh) * 2022-07-25 2024-04-26 南通大学 2,4,5-三取代嘧啶羟胺酰衍生物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127996C (pt) * 1963-11-19
OA12097A (en) * 1999-11-30 2006-05-04 Pfizer Prod Inc 2,4-Diaminopyrimidine compounds useful as immunosuppressants.
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
US6630469B2 (en) * 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
WO2003011836A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
MXPA04004178A (es) * 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20060133552A (ko) 2006-12-26
CN1910159A (zh) 2007-02-07
RU2006129469A (ru) 2008-02-27
WO2005068437A1 (en) 2005-07-28
AU2005205167A1 (en) 2005-07-28
CA2551770A1 (en) 2005-07-28
JP2007517831A (ja) 2007-07-05
EP1727806A1 (en) 2006-12-06
US20050209231A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
EP2727998A3 (en) Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells
MY159971A (en) Multipotent/pluripotent cells and methods
HRP20150828T8 (hr) Kompozicije i postupci in vitro i in vivo ciljanog oslobađanja lijeka u stanicama sisavaca, preko intaktnih mini-stanica izvedenih iz bakterija
IL194438A (en) Diarrhylthiohydantoin Compounds, Pharmaceuticals Containing Them, Syntheses Methods and In Vitro Methods for Contacting them with Mammalian Cells
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
EP2155859A4 (en) FORMULATIONS AND METHODS FOR CULTIVATING EMBRYONIC STEM CELLS
MX375111B (es) Fenil acetato de l-ornitina y métodos para elaborar el mismo.
MX2012009088A (es) Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
IL236427A0 (en) Human anti-23-il antibodies, preparations, methods and uses
IL181438A0 (en) Culturing human embryonic stem cells
WO2009111586A3 (en) Autonomous in vitro evolution
WO2010111409A3 (en) Pluripotent stem cells
SI2452694T1 (sl) Protitelesa proti-IL-23, sestavki in postopki uporabe
WO2007047766A3 (en) Methods for rejuvenating cells in vitro and in vivo
PL2089511T3 (pl) Rozrost in vitro komórek pochodzących z tkanki pępowinowej wykorzystujących mikronośniki
EP2162534A4 (en) METHOD AND COMPOSITIONS RELATED TO CD34 STEM CELLS
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
IN2012DN02452A (pt)
DK2094325T3 (da) Fremstilling af væv til meniskimplantation
WO2008005520A3 (en) Temperature-responsive microcarrier
AR118760A2 (es) Coaglomerados de manitol y de almidón granular comprimibles y de libre fluidez
AU321832S (en) Neck support
MX2009004435A (es) Tinturas dispersas, su preparacion y su uso.
MX2010002028A (es) Metodos y composiciones para modular celulas t.
WO2009092005A3 (en) Methods of generating cardiomyocytes and cardiac progenitors and compositions

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.